Glufosfamide is under clinical development by Eleison Pharmaceuticals and currently in Phase III for Metastatic Adenocarcinoma of The Pancreas. According to GlobalData, Phase III drugs for Metastatic Adenocarcinoma of The Pancreas have a 38% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Glufosfamide’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Glufosfamide overview

Glufosfamide is under development for the treatment of metastatic pancreatic adenocarcinoma. The drug candidate is administered intravenously. Glufosfamide is beta-D-glucosyl-isophosphoramide mustard and a glucose-conjugated prodrug. It is an analogue of ifosfamide. It acts as an alkylating agent and stops tumor growth by cross-linking bases in DNA double-helix strands, directly attacking DNA. The drug candidate was also under development for the treatment of recurrent sensitive small-cell lung cancer, soft tissue sarcoma, epithelial ovarian cancer, peritoneal serous cancer, or carcinoma of the fallopian tube.

Eleison Pharmaceuticals overview

Eleison Pharmaceuticals is a drug development company that acquires, develops, and commercializes clinical stage drug candidates for orphan cancers. The company’s pipeline products include glufosfamide and inhaled lipid-complexed cisplatin. Its glufosfamide is an analog of chemotherapeutic agent for treatment of metabolically active tumors and hypoxic tumor regions. Eleison Pharmaceuticals’ inhaled lipid-complexed cisplatin is a sustained release formulation of cisplatin in a nanoscale lipid based complex used for pediatric osteosarcoma – bone cancer. The company provides clinical trials for pancreatic cancer and osteosarcoma. Eleison Pharmaceuticals is headquartered in Princeton, New Jersey, the US.

For a complete picture of Glufosfamide’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.